Shots:
- Novartis has reported the topline P-III (RemIND) trial data assessing remibrutinib (PO) vs PBO in adults with CIndU inadequately controlled by H1-antihistamines
- Trial showed higher CR rates at Wk. 12 across symptomatic dermographism (29.3% vs 14%), cold urticaria (56.3% vs 14.6%), & cholinergic urticaria (29.3% vs 15.8%), with responses emerging as early as Wk. 2 in 2 subtypes; data were presented at EAACI’26
- Additionally, Novartis has submitted an sNDA to the FDA seeking approval of Rhapsido for symptomatic dermographism & plans to pursue additional regulatory filings worldwide throughout 2026
Ref: Globenewswire | Image: Novartis |Press Release
Related News: Novartis Reports the Biomarker Data from P-I/II (FORTITUDE) study of del-brax in FSHD
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
